MOBERG DERMA HAS COMPLETED RECRUITMENT FOR MOB-015 PHASE II CLINICAL STUDY

Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 237 patients with nail fungus (onychomycosis) to participate in the ongoing MOB-015 phase II study. MOB-015 is the company’s second-generation topical treatment for nail fungus.

The purpose of the study, which includes 237 patients, is to confirm the validity of the MOB-015 product concept and to provide the basis for a phase III program as well as licensing. Patients will be followed-up during 12 months and the endpoints normally accepted by FDA, EMA and other relevant authorities for nail fungus are used.

“We are very pleased that patient recruitment has been successfully completed and that the study is proceeding according to plan. MOB-015 has the potential to be the future market leader for the treatment of nail fungus,” said Peter Wolpert, CEO of Moberg Derma.

About MOB-015 and nail fungus
MOB-015 is a new topical treatment for nail fungus (onychomycosis) with fungicidal, keratolytic and emollient properties. Moberg Dermas patent-pending formulation technology facilitates high concentrations of a fungicidal substance to be transported in and through nail tissue. In pre-clinical studies on human nails, more than tenfold concentrations of the antifungal substance have been detected, compared to the concentrations measured in the nail with successful oral treatment. As MOB-015 is applied locally, the side effects associated with oral treatment are avoided.

Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

For further information, please contact:
Peter Wolpert, President and CEO of Moberg Derma

Telephone: +46 8 522 307 00
Mobile: +46 70- 735 71 35
E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se

About this information
Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:30 am (CET) on September 12th, 2011.

About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s first product Emtrix®- for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.se

Tags:

About Us

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in more than 800 patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Contacts

Subscribe

Documents & Links